Cetuximab companion diagnostic - BioMarker Strategies

Drug Profile

Cetuximab companion diagnostic - BioMarker Strategies

Latest Information Update: 18 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioMarker Strategies
  • Class Diagnostic agents
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Head and neck cancer

Most Recent Events

  • 04 Oct 2017 Clinical trials in Head and neck cancer (Diagnosis) in USA (unspecified route)
  • 03 Oct 2017 BioMarker Strategies receives SBIR grant from National Cancer Institute for Cetuximab companion diagnostic development in Head and neck cancer (Diagnosis)
  • 03 Oct 2017 BioMarker Strategies has patent protection for PathMAP Functional Signaling Profile technology in USA, Europe, Australia, Japan and Singapore
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top